{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:53:54Z","timestamp":1790013234251,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T00:00:00Z","timestamp":1443398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Galderma R & D"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Facial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate patient\u2010reported outcomes, as well as efficacy and safety, in subjects with self\u2010perceived severe erythema treated with brimonidine gel 0.33% compared to vehicle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An 8\u2010day multicenter, randomized study comparing once\u2010daily brimonidine gel 0.33% with vehicle gel using a facial redness questionnaire, subject satisfaction questionnaire and a patient diary of facial redness control to assess patient\u2010reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 92 included subjects with self\u2010perceived severe erythema, very few were satisfied with their appearance at baseline (4.2% brimonidine group, 0 vehicle group). On Day 8, significantly more brimonidine group subjects were satisfied with their facial appearance compared to vehicle group (36.9% vs. 21.5%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05), with the overall treatment effect (69.6% vs. 40.4%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01), and with the improvement in their facial redness (67.4% vs. 33.3%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). More brimonidine group subjects were able to control their facial redness daily (e.g. 83.0% vs. 38.9% on Day 1). On Day 8, significantly more brimonidine group subjects than vehicle group had at least a one\u2010grade improvement from baseline in the Clinician Erythema Assessment score (71.7% vs. 35.7%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0011) and Patient Self\u2010Assessment score (76.1% vs. 47.6%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). More subjects in the brimonidine group (29.2%) reported treatment\u2010related adverse events than in the vehicle group (15.9%) but most were mild and transient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Once\u2010daily brimonidine gel 0.33% allowed patients to rapidly control their facial redness and significantly improved patient\u2010reported outcomes in the treatment of persistent facial erythema of rosacea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.13305","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T20:57:47Z","timestamp":1443473867000},"page":"2405-2410","source":"Crossref","is-referenced-by-count":52,"title":["Brimonidine gel 0.33% rapidly improves patient\u2010reported outcomes by controlling facial erythema of rosacea: a randomized, double\u2010blind, vehicle\u2010controlled study"],"prefix":"10.1111","volume":"29","author":[{"given":"A.M.","family":"Layton","sequence":"first","affiliation":[{"name":"Harrogate and District NHS Foundation Trust Harrogate UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaller","sequence":"additional","affiliation":[{"name":"Department of Dermatology T\u00fcbingen University Hospital T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Homey","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Faculty University of D\u00fcsseldorf D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology Charit\u00e9 Medical School Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Bewley","sequence":"additional","affiliation":[{"name":"Whipps Cross University Hospital and the Royal London Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Center for Dermatology, Allergology, and Surgical Dermatology Helios Clinic Wuppertal Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nohlg\u00e5rd","sequence":"additional","affiliation":[{"name":"L\u00e4karhuset Odenplan Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Sarwer","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Surgery Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kerrouche","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D SNC Sophia Antipolis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.M.","family":"Ma","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D SNC Sophia Antipolis France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.043"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(11)70089-8"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.048"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09894.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.036"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"e_1_2_6_10_1","first-page":"623","article-title":"Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease","volume":"20","author":"Feldman SR","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_6_11_1","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents","volume":"92","author":"Del Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_6_12_1","first-page":"134","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea","volume":"93","author":"Del Rosso JQ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"key":"e_1_2_6_15_1","first-page":"650","article-title":"Efficacy and safety of once\u2010daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double\u2010blind, and vehicle\u2010controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_16_1","first-page":"56","article-title":"Long\u2010term safety and efficacy of once\u2010daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1\u2010year open\u2010label study","volume":"13","author":"Moore A","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06895.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0716"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12587"},{"key":"e_1_2_6_20_1","first-page":"33","article-title":"Optimizing the use of topical brimonidine in rosacea management: panel recommendations","volume":"14","author":"Tanghetti EA","year":"2015","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T04:03:44Z","timestamp":1695528224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/jdv.13305"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13305","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,28]]}}}